Etiology of hepatocellular carcinoma in Latin America: A prospective, multicenter, international study

Annals of Hepatology

Volumn 9, Issue 1, 2010, Pages 66-69

  Fassio, Eduardo ^a   Díaz, Solangel ^b   Santa, Catalina ^c   Reig, María Elisa ^d   Artola, Yamila Martínez ^e   de Mattos, Angelo Alves ^f   Míguez, Carlos ^g   Galizzi, Joao ^h   Zapata, Rodrigo ⁱ   Ridruejo, Ezequiel ^j   de Souza, Francisco Carlos ^k   Hernández, Nelia ^l   Pinchuk, Leonardo ^m  

^a HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

^b Policlinica Metropolitana   (Venezuela)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^d HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^e Hospital Dr J Méndez ^*  (Argentina)

^f Santa Casa de Misericordia de Goiania   (Brazil)

^g HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

^h HOSPITAL FELÍCIO ROCHO   (Brazil)

ⁱ UNIVERSIDAD DEL DESARROLLO   (Chile)

^j CEMIC   (Argentina)

^k Hospital Mater Dei   (Brazil)

^l HOSPITAL DE CLÍNICAS   (Uruguay)

^m HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

more..

Author keywords

Alcoholic cirrhosis; BCLC staging system; Cryptogenic cirrhosis; Hepatitis B; Hepatitis C

Indexed keywords

ALCOHOL; SORAFENIB;

ADULT; AGE; AGED; ALCOHOLISM; ARTICLE; CANCER RISK; CANCER STAGING; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; RISK FACTOR; SEX DIFFERENCE; SEX RATIO; SOUTH AND CENTRAL AMERICA; ALCOHOL LIVER CIRRHOSIS; CHRONIC DISEASE; CLINICAL TRIAL; INCIDENCE; INTERNATIONAL COOPERATION; LIVER TUMOR; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY;

AGED; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; INCIDENCE; INTERNATIONAL COOPERATION; LATIN AMERICA; LIVER CIRRHOSIS, ALCOHOLIC; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 77954583932     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31681-3     Document Type: Article

References (41)

1. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liv Dis 2005; 25: 143-154.
2. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
3. Kemp W, Pianko S, Nguyen S, Bailey MJ, Roberts SK. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol 2005; 20: 873-881.
4. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez Tapias, JM, Ventura M, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-1006.
5. Colombo M, Kuo G, Choo QL, Donato MF, del Ninno E, Tom-masini MA, Dioquardi N, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2: 1006-1008.
6. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
7. Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fa-sola M, Gellatti U, et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Hepatology 1997; 26: 579-584.
8. Hassan MM, Hwang L-Y, Hatten CJ, Swaim M, Li D, Abbruz-zese JL, Beasley P, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-1213.
9. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-1354.
10. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatoce-llular carcinoma. Gastroenterology 2004; 127: S87-S96.
11. Goncalves CS, Pereira FE, Gayotto LC. Hepatocellular carcinoma in Brazil: report of a national survey (Florianopolis, SC, 1995). Rev Inst Med Trop Sao Paulo 1997; 39: 165-170.
12. Mondragón-Sánchez R, Garduño-López AL, Hernández-Cas-tillo E, Gómez-Gómez E, Ruiz-Molina JM. Hepatocellular carcinoma and hepatitis C in Mexico. Hepatogastroente-rology 2005; 52: 1159-1162.
13. Ruiz E, Sanchez J, Celis J, Payet E, Berrospi F, Chavez I, Young F. Short and long-term results of liver resection for hepatocarcinoma in Peru: a Peruvian single center experience on 232 cases. Rev Gastroenterol Peru 2007; 27: 223-237.
14. Ruiz E, Almonte M MPH, Pizarro R, Celis J, Montalbelti JA, Urbano R. Hepatitis B and C virus infection as risk factors for hepatocarcinoma in Peru: case and control study. Rev Gastroenterol Peru 1998; 18: 199-212.
15. Muñoz G, Velazco M, Thiers V, Hurtado C, Brahm J, La-rrondo-Lillo M, Guglielmetti A, et al. Prevalence and genotypes of hepatitis C virus in blood donors and in patients with chronic liver disease and hepatocarcinoma in a Chilean population. Rev Med Chil 1998; 126: 1035-1042.
16. Fassio E, Míguez C, Soria S, Palazzo F, Gadano A, Adrover R, Landeira G, et al. Etiology of hepatocellular carcinoma in Argentina: results of a multicenter retrospective study. Acta Gastroenterol Latinoamer 2009; 39: 47-52.
17. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, et al. Natural history of hepato-cellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-928.
18. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
19. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421-430.
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
21. Strader DB, Wright T, Thomas DL, Seef LB. Diagnosis, management and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
22. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
23. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 1321-1328.
24. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cançado EL, Chapman RW, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938.
25. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steato-hepatitis: Summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-1219.
26. Tagger A, Donato F, Ribero ML, Chiesa R, Portera G, Ge-latti U, Albertini A, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Bresica HCC study. Int J Cancer 1999; 81: 695-699.
27. Miyakawa H, Sato C, Tazawa J, Izumi N, Hattori K, Ebata A, Maeda M, et al. A prospective study on hepatocellular carcinoma in liver cirrhosis: respective roles of alcohol and hepatitis C virus infection. Alcohol alcohol 1994; 29(Suppl. 1): 75-79.
28. Yu MW, You SL, Chang AS, Lu SN, Liaw YF, Chen CJ. Association between hepatitis C virus antibodies and hepato-cellular carcinoma in Taiwan. Cancer Res 1991; 51: 5621-5625.
29. Tanaka K, Hirohata T, Koga S, Sugimachi K, Kanematsu T, Ohryohji F, Nawata H, et al. Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res 1991; 51: 2842-2847.
30. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepato-logy 1993; 18: 47-53.
31. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow up study after histologic diagnosis. Cancer 2000; 89: 53-59.
32. Ratziu V, Bonyhay L, di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryp-togenic cirrhosis. Hepatology 2002; 35: 1485-1493.
33. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10: S69-S73.
34. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37(Suppl. 2): S88-S94.
35. Caldwell SH, Crespo DM, Scott Kang H, Al-Osaimi AMS. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127: S97-S103.
36. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468.
37. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity and mortality from cancer in a pros-pectively studied cohort of US adults. N Engl J Med 2003; 348: 1625-1638.
38. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-689.
39. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008; 132: 1761-1766.
40. Paradis V, Zalinsky S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859.
41. El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, McGlynn KA. Treatment and outcomes of he-patocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44: 158-166.